1FM6 | D:; X: | THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. |
1FM9 | D: | THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES. |
1I7I | A:; B: | CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242 |
1K74 | D: | THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES. |
1KNU | A:; B: | LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST |
1NYX | A:; B: | LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST |
1PRG | A:; B: | LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA |
1RDT | D: | CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER |
1WM0 | X: | PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND |
1ZEO | A:; B: | CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST |
2G0G | A:; B: | STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES |
2G0H | A:; B: | STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES |
2GTK | A: | STRUCTURE-BASED DESIGN OF INDOLE PROPIONIC ACIDS AS NOVEL PPARAG CO-AGONISTS |
2HFP | A: | CRYSTAL STRUCTURE OF PPAR GAMMA WITH N-SULFONYL-2-INDOLE CARBOXAMIDE LIGANDS |
2I4J | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE) |
2I4P | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS. |
2I4Z | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS. |
2P4Y | A:; B: | CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR |
2POB | A:; B: | PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709 |
2PRG | A:; B: | LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA |
2Q59 | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20 |
2Q5P | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24 |
2Q5S | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA |
2Q61 | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145 |
2Q6R | A:; B: | CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147 |
2Q6S | A:; B: | 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES |
2Q8S | A:; B: | X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST |
2XKW | A:; B: | LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE |
2ZK0 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN |
2ZK1 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA12,14-PROSTAGLANDIN J2 |
2ZK2 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA12,14-PROSTAGLANDIN J2 |
2ZK3 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO-EICOSATETRAENOIC ACID |
2ZK4 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO-EICOSATETRAENOIC ACID |
2ZK5 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233 |
2ZK6 | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY |
2ZNO | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703 |
2ZVT | A:; B: | CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA12,14-PROSTAGLANDIN J2 |
3AN3 | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S |
3AN4 | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R |
3B0Q | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555 |
3B0R | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM |
3B1M | A: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR CERCO-A |
3B3K | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175 |
3BC5 | A: | X-RAY CRYSTAL STRUCTURE OF HUMAN PPAR GAMMA WITH 2-(5-(3-(2-(5-METHYL-2-PHENYLOXAZOL-4-YL)ETHOXY)BENZYL)-2-PHENYL-2H-1, 2,3-TRIAZOL-4-YL)ACETIC ACID |
3D6D | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER) |
3ET0 | A:; B: | STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)-PROPIONIC ACID |
3ET3 | A: | STRUCTURE OF PPARGAMMA WITH 3-[5-METHOXY-1-(4-METHOXY-BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID |
3FEJ | A: | DESIGN AND BIOLOGICAL EVALUATION OF NOVEL, BALANCED DUAL PPARA/G AGONISTS |
3G9E | A: | ALEGLITAAR. A NEW. POTENT, AND BALANCED DUAL PPARA/G AGONIST FOR THE TREATMENT OF TYPE II DIABETES |
3H0A | D: | CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID, CO-ACTIVATOR PEPTIDE, AND A PARTIAL AGONIST |
3HO0 | A:; B: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID |
3HOD | A:; B: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID |
3IA6 | A:; B: | X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST |
3K8S | A:; B: | CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384 |
3KMG | A:; D: | THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR, GSK538, AND AN SRC-1 PEPTIDE |
3LMP | A: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR |
3NOA | A:; B: | CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST |
3OSI | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA) |
3OSW | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA) |
3PBA | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA) |
3PO9 | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN |
3PRG | A: | LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR |
3QT0 | A: | REVEALING A STEROID RECEPTOR LIGAND AS A UNIQUE PPARGAMMA AGONIST |
3R5N | A: | CRYSTAL STRUCTURE OF PPARGAMMALBD COMPLEXED WITH THE AGONIST MAGNOLOL |
3R8A | A:; B: | X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY |
3R8I | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86) |
3SZ1 | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID |
3TY0 | A:; B: | STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3-((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-2,3-DIHYDRO-1H-BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-2,4-DIONE |
3U9Q | A: | LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH DECANOIC ACID AND PGC-1A PEPTIDE |
3V9T | A: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR |
3V9V | A: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR |
3V9Y | A: | CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR |
3VJH | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35 |
3VJI | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53 |
3VSO | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21 |
3VSP | A:; B: | HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28 |
4E4K | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21 |
4E4Q | A:; B: | CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214 |
4EM9 | A:; B: | HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS |
4EMA | A:; B: | HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE |
4JAZ | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS-RESVERATROL |
4JL4 | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID] |
4PRG | A:; B:; C:; D: | 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL |